Anti–CTLA-4 therapy requires an Fc domain for efficacy

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

(2017) Frederick Arce Vargas et al.   IMMUNITY

Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies

(2017) Bryan C Barnhart et al.   IMMUNOLOGY AND CELL BIOLOGY

Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells

(2017) Mohammad Rashidian et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Localized CD47 blockade enhances immunotherapy for murine melanoma

(2017) Jessica R. Ingram et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

(2017) Udupi A. Ramagopal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

(2017) Rodrigo Vazquez-Lombardi et al.   Nature Communications

PD-L1 is an activation-independent marker of brown adipocytes

(2017) Jessica R. Ingram et al.   Nature Communications

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract

(2017) Michael Dougan   Frontiers in Immunology

Coinhibitory Pathways in Immunotherapy for Cancer

(2016) Susanne H. Baumeister et al.   Annual Review of Immunology

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity

(2015) Alison M. Paterson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninvasive imaging of immune responses

(2015) Mohammad Rashidian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Use of 18F-2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer

(2015) Mohammad Rashidian et al.   ACS Central Science

Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4

(2014) Sebastian Zeissig et al.   GUT

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

(2014) Desirée Schubert et al.   NATURE MEDICINE

64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues

(2014) Kei Higashikawa et al.   PLoS One

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

(2014) H. S. Kuehn et al.   SCIENCE

Nanobodies: Natural Single-Domain Antibodies

(2013) Serge Muyldermans   Annual Review of Biochemistry

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

IAP inhibitors enhance co-stimulation to promote tumor immunity

(2010) Michael Dougan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types

(2010) K. De Groeve et al.   JOURNAL OF NUCLEAR MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

3V: cavity, channel and cleft volume calculator and extractor

(2010) N. R. Voss et al.   NUCLEIC ACIDS RESEARCH

Immune Therapy for Cancer

(2008) Michael Dougan et al.   Annual Review of Immunology

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE